{"product_id":"opening-the-gates-how-flexible-eligibility-rules-could-let-more-pancreatic-and-biliary-cancer-patients-join-clinical-trials","title":"Opening the Gates: How Flexible Eligibility Rules Could Let More Pancreatic and Biliary Cancer Patients Join Clinical Trials","description":"\u003cp\u003eIn a review of 509 patients with pancreatic or biliary tract cancer who consented to join clinical trials but ultimately could not take part, researchers found that about 1 in 7 (13.6%, or 69 patients) were excluded for reasons that might have been safely relaxed. Most of these potentially modifiable exclusions (PMEs) involved borderline laboratory values — mildly abnormal liver or kidney tests, or blood counts just below cutoff limits — rather than true safety threats. The authors conclude that loosening rigid eligibility rules, many inherited from the era of older chemotherapy drugs, could let more real-world patients access experimental treatments without putting them at greater risk.\u003c\/p\u003e\n\n\u003ch1\u003eOpening the Gates: How Flexible Eligibility Rules Could Let More Pancreatic and Biliary Cancer Patients Join Clinical Trials\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Trial Eligibility Rules Matter\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Study Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#screen-failure-reasons\"\u003eWhy Patients Failed Screening: The Full Picture\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#modifiable-exclusions\"\u003ePotentially Modifiable Exclusions: The 69 Patients Who Might Have Qualified\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#specific-cases\"\u003eDetailed Examples of Modifiable Exclusions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Next Steps\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a review of 509 patients with pancreatic or biliary tract cancer, 69 (13.6%) had exclusions that might have been safely relaxed.\u003c\/li\u003e\n\u003cli\u003eMost potentially modifiable exclusions involved borderline laboratory values, such as mildly abnormal liver or kidney tests or blood counts just below cutoff limits.\u003c\/li\u003e\n\u003cli\u003eOrgan function and blood count rules accounted for 43% and 25% of potentially modifiable exclusions, respectively.\u003c\/li\u003e\n\u003cli\u003eThe authors suggest that loosening rigid eligibility rules could let more real-world patients access experimental treatments without greater risk.\u003c\/li\u003e\n\u003cli\u003eAny relaxation of criteria must still preserve patient safety and scientific integrity, and prospective research is needed to evaluate broadened eligibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Trial Eligibility Rules Matter\u003c\/h2\u003e\n\n\u003cp\u003eClinical trials are the foundation of every new cancer treatment. The rules that decide who can join — called \u003cstrong\u003eeligibility criteria\u003c\/strong\u003e — define the study population. These rules exist to keep patients safe and to keep the research clean and trustworthy.\u003c\/p\u003e\n\n\u003cp\u003eBut there is a growing problem. Rules that are too strict can shut out a large share of real-world patients who might actually benefit from a new treatment. The consequences reach far beyond a single patient. Most studies fail to recruit enough people within their planned timelines, and the results may not reflect how a drug performs in everyday practice.\u003c\/p\u003e\n\n\u003cp\u003eThe scale of the problem is striking: only \u003cstrong\u003e7.1%\u003c\/strong\u003e of patients with cancer in the United States currently take part in a clinical trial. That means fewer than 1 in 14 patients ever joins one.\u003c\/p\u003e\n\n\u003cp\u003eCancer treatment has changed dramatically. It has moved from traditional \u003cstrong\u003ecytotoxic chemotherapy\u003c\/strong\u003e (drugs that kill fast-dividing cells) toward \u003cstrong\u003etargeted molecular agents\u003c\/strong\u003e (drugs aimed at specific cancer mutations) and \u003cstrong\u003eimmune therapeutics\u003c\/strong\u003e (treatments that help the immune system attack cancer). Yet many eligibility rules were written decades ago, during the chemotherapy era, and were carried forward without being updated. Studies show these criteria have grown both more numerous over time and less representative of the typical patient with cancer.\u003c\/p\u003e\n\n\u003cp\u003eThis mismatch matters most for two hard-to-treat diseases: \u003cstrong\u003ebiliary tract cancer (BTC)\u003c\/strong\u003e, which arises in the bile ducts or gallbladder, and \u003cstrong\u003epancreatic ductal adenocarcinoma (PDAC)\u003c\/strong\u003e, the most common form of pancreatic cancer. Both are becoming more common and both carry a poor prognosis. For patients with advanced disease, median overall survival (the point at which half of patients are still alive) is only about \u003cstrong\u003e12 months\u003c\/strong\u003e. New options are urgently needed, which makes trial access especially important.\u003c\/p\u003e\n\n\u003cp\u003eDespite recent calls to modernize eligibility criteria, few studies have examined how these rules play out specifically in pancreatic and biliary cancers. This research fills that gap.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Study Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis was a \u003cstrong\u003eretrospective study\u003c\/strong\u003e — meaning researchers looked backward at records already collected rather than enrolling new patients. It took place at The University of Texas MD Anderson Cancer Center in Houston.\u003c\/p\u003e\n\n\u003cp\u003eThe team reviewed all adults with confirmed biliary tract cancer or pancreatic ductal adenocarcinoma who were found ineligible for cancer clinical trials between \u003cstrong\u003eAugust 2019 and November 2024\u003c\/strong\u003e. Patients were identified by systematically reviewing the screening logs of every trial during that period that included people with BTC and\/or PDAC, so that no potential candidate was missed.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers focused on \u003cstrong\u003escreen-failed patients\u003c\/strong\u003e. This term covers anyone who was referred for screening and gave \u003cstrong\u003einformed consent\u003c\/strong\u003e (formal permission after learning the risks and details) but then did not join the trial for any reason. That includes not meeting eligibility criteria, withdrawing consent, or failing other protocol-specific requirements.\u003c\/p\u003e\n\n\u003cp\u003ePatients with insufficient documentation in their medical records were excluded to protect data quality. Clinical information came from electronic health records and was cross-checked against screening logs kept by research coordinators.\u003c\/p\u003e\n\n\u003cp\u003eThe heart of the study was identifying \u003cstrong\u003epotentially modifiable exclusions (PMEs)\u003c\/strong\u003e. A PME is any factor that caused screening failure but could possibly have been changed or waived — allowing the patient to join the trial without threatening safety or study integrity.\u003c\/p\u003e\n\n\u003cp\u003eCritically, PMEs were not predetermined. They were identified only after a full review of each patient's record, weighing:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eOther medical conditions (comorbidities)\u003c\/li\u003e\n  \u003cli\u003eLaboratory results\u003c\/li\u003e\n  \u003cli\u003eHow stable the patient's clinical condition was\u003c\/li\u003e\n  \u003cli\u003eHow the investigational drug works (its mechanism of action)\u003c\/li\u003e\n  \u003cli\u003eDocumented safety data from similar drugs\u003c\/li\u003e\n  \u003cli\u003eHow the patient later tolerated standard therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTwo experienced medical oncologists independently applied a structured framework. They classified an exclusion as potentially modifiable when the patient's value was within \u003cstrong\u003e10%–15%\u003c\/strong\u003e of the eligibility threshold and was unlikely to significantly affect patient safety or study integrity. All co-investigators agreed on this approach.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also tracked what happened to each patient with a PME afterward, to see how they fared. Finally, they used \u003cstrong\u003edescriptive statistics\u003c\/strong\u003e (simple summaries of the data) to report how common screen failures were and what caused them.\u003c\/p\u003e\n\n\u003ch2 id=\"screen-failure-reasons\"\u003eWhy Patients Failed Screening: The Full Picture\u003c\/h2\u003e\n\n\u003cp\u003eAcross 18 clinical trials, \u003cstrong\u003e585 patients\u003c\/strong\u003e failed screening. Of these, 76 were excluded because of incomplete information, leaving \u003cstrong\u003e509 patients\u003c\/strong\u003e for analysis: \u003cstrong\u003e367 with pancreatic cancer\u003c\/strong\u003e and \u003cstrong\u003e142 with biliary tract cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe 18 trials included 10 for biliary tract cancer and 8 for pancreatic cancer. By phase:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e4 phase 1 trials (early safety and dosing studies)\u003c\/li\u003e\n  \u003cli\u003e7 phase 1\/2 trials\u003c\/li\u003e\n  \u003cli\u003e6 phase 2 trials (testing effectiveness)\u003c\/li\u003e\n  \u003cli\u003e1 phase 3 trial (large, definitive comparison)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAll trials enrolled patients with advanced cancer. Eight trials tested targeted therapy, seven tested combinations of chemotherapy plus targeted therapy, two tested cellular therapy or cancer vaccines, and one tested a targeted therapy combined with an immune checkpoint inhibitor (a drug that releases brakes on the immune system).\u003c\/p\u003e\n\n\u003cp\u003eThe three most common reasons for screening failure were:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient declined or withdrew consent\u003c\/strong\u003e — 99 patients (19%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCoexisting severe comorbidities\u003c\/strong\u003e — 59 patients (12%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSuboptimal organ function\u003c\/strong\u003e (kidney or liver) — 56 patients (11%)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eOther reasons, in order of frequency, were:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eAbsence of a required biomarker — 49 patients (10%)\u003c\/li\u003e\n  \u003cli\u003eScreening error — 44 patients (9%)\u003c\/li\u003e\n  \u003cli\u003eResearch team logistics — 43 patients (8%)\u003c\/li\u003e\n  \u003cli\u003eLack of a biospecimen (tissue or blood sample) — 36 patients (7%)\u003c\/li\u003e\n  \u003cli\u003ePrevious therapy exceeding inclusion criteria limits — 28 patients (6%)\u003c\/li\u003e\n  \u003cli\u003ePhysician's decision or discretion — 25 patients (5%)\u003c\/li\u003e\n  \u003cli\u003eSuboptimal performance status (overall fitness level) — 21 patients (4%)\u003c\/li\u003e\n  \u003cli\u003eConcurrent or previous malignancy (another cancer) — 21 patients (4%)\u003c\/li\u003e\n  \u003cli\u003eCohort closed for enrollment — 12 patients (2%)\u003c\/li\u003e\n  \u003cli\u003eConcomitant therapy that may interact with the study drug — 11 patients (2%)\u003c\/li\u003e\n  \u003cli\u003eLack of measurable disease — 5 patients (1%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWithin the group who declined to participate, the reasons break down as follows:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePreference for standard care — 23 patients (4%)\u003c\/li\u003e\n  \u003cli\u003eTravel constraints — 22 patients (4%)\u003c\/li\u003e\n  \u003cli\u003eCompeting trial availability — 5 patients (1%)\u003c\/li\u003e\n  \u003cli\u003eConcerns about adverse events (side effects) — 4 patients (1%)\u003c\/li\u003e\n  \u003cli\u003eFinancial limitations — 3 patients (1%)\u003c\/li\u003e\n  \u003cli\u003eUnknown reasons — 42 patients (8%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThat last figure stands out. Nearly half of the patients who withdrew consent gave no documented reason. This is a meaningful gap in understanding, and it points to opportunities both to improve trial design and to better educate patients.\u003c\/p\u003e\n\n\u003ch2 id=\"modifiable-exclusions\"\u003ePotentially Modifiable Exclusions: The 69 Patients Who Might Have Qualified\u003c\/h2\u003e\n\n\u003cp\u003eAmong the 509 patients analyzed, \u003cstrong\u003e69 patients (13.6%)\u003c\/strong\u003e — roughly 1 in 7 — had exclusions that the expert reviewers judged potentially modifiable. These PMEs were spread evenly across trials, meaning no single study was the culprit.\u003c\/p\u003e\n\n\u003cp\u003eThe two largest categories were:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrgan function abnormalities\u003c\/strong\u003e — 30 patients (43% of PMEs)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHematologic (blood) abnormalities\u003c\/strong\u003e — 17 patients (25% of PMEs)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWithin organ function, the specific issues were strict cutoffs for \u003cstrong\u003eliver function\u003c\/strong\u003e (16 patients, 23%) and \u003cstrong\u003ekidney function\u003c\/strong\u003e (14 patients, 20%).\u003c\/p\u003e\n\n\u003cp\u003eWithin blood abnormalities, the breakdown was:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHemoglobin\u003c\/strong\u003e (oxygen-carrying protein in red blood cells) — 5 patients (7%), with values in the grade 1–2 range (from below 10 down to 8 g\/dL)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbsolute neutrophil count\u003c\/strong\u003e (a type of white blood cell that fights infection) — 4 patients (6%), in the grade 1–2 range (from below 1500 down to 1000\/mm³)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlatelet count\u003c\/strong\u003e (cells that help blood clot) — 8 patients (12%). Five had grade 1 low platelets (from below the lower limit of normal down to 75,000\/mm³), and three had grade 1–2 low platelets (from below 75,000 down to 50,000\/mm³)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditional organ function details were equally mild. Fourteen patients had \u003cstrong\u003egrade 2 creatinine clearance\u003c\/strong\u003e (a measure of kidney filtering) between 60 and 30 mL per minute. For bilirubin (a liver pigment), three patients had grade 1 elevation (above the upper limit of normal up to 1.5 times that limit) and ten had grade 2 elevation (from 1.5 to 3.0 times the limit). Three patients had grade 2 elevation of liver enzymes (from 3.9 to 5 times the upper limit of normal).\u003c\/p\u003e\n\n\u003cp\u003eBeyond lab values, other PMEs included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePrevious or concurrent malignancy — 6 patients (9%)\u003c\/li\u003e\n  \u003cli\u003eTumor-specific criteria — 6 patients (9%)\u003c\/li\u003e\n  \u003cli\u003eHepatitis B or C viral infection — 3 patients (4%)\u003c\/li\u003e\n  \u003cli\u003eRecent chemotherapy or radiotherapy — 3 patients (5%)\u003c\/li\u003e\n  \u003cli\u003eHistory of alcohol or substance use — 2 patients (3%)\u003c\/li\u003e\n  \u003cli\u003eHistory of gastrointestinal bleeding — 1 patient (1%)\u003c\/li\u003e\n  \u003cli\u003eOngoing medication conflicts — 1 patient (1%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers plotted how far each patient's values deviated from the required thresholds. This visualization, shown as a boxplot, revealed that most deviations were small rather than extreme.\u003c\/p\u003e\n\n\u003ch2 id=\"specific-cases\"\u003eDetailed Examples of Modifiable Exclusions\u003c\/h2\u003e\n\n\u003cp\u003eThe individual stories behind these numbers help explain why the authors see room for flexibility.\u003c\/p\u003e\n\n\u003cp\u003eAmong the six patients excluded because of another cancer, two had early-stage non–small cell lung cancer (stage IA and stage IB), and one had a localized basal cell carcinoma (a common, highly treatable skin cancer). All three were diagnosed within 5 years of screening and were treated with curative intent. The other three had chronic lymphocytic leukemia (a slow-growing blood cancer) under surveillance, breast cancer treated 19 years earlier, and cervical cancer treated 25 years earlier. Importantly, none of these six patients experienced progression of their earlier cancer during screening or during subsequent therapy.\u003c\/p\u003e\n\n\u003cp\u003eThree patients were excluded because of hepatitis B or C infection. All three had viral DNA levels within normal limits and normal alanine transaminase levels (a liver enzyme marker). In other words, their infections were well controlled.\u003c\/p\u003e\n\n\u003cp\u003eTwo patients were excluded for a history of alcohol or substance use. One had been abstinent for 5 months when the trial required 6 months. The other had been abstinent for 17 years.\u003c\/p\u003e\n\n\u003cp\u003eOne patient was excluded for gastrointestinal bleeding. On endoscopy, he had duodenitis (inflammation of the first part of the small intestine) without varices (enlarged veins) or peptic ulcers. He never had a drop in hemoglobin or unstable vital signs, and he never needed a red blood cell transfusion.\u003c\/p\u003e\n\n\u003cp\u003eThree patients were excluded for recent chemotherapy or radiotherapy when the protocol required a 6-month washout period (a waiting period after treatment). One had completed concurrent chemoradiotherapy 5 months before screening, another at 5.5 months, and one had received adjuvant chemotherapy 5 months before screening. Each fell just short of the required window.\u003c\/p\u003e\n\n\u003cp\u003eOne patient was excluded for ongoing treatment with \u003cstrong\u003eleuprolide\u003c\/strong\u003e, a gonadotropin-releasing hormone agonist (a drug that suppresses certain hormones). Leuprolide has no known interaction with the study drug and no significant immune-suppressing or bone-marrow-suppressing effects.\u003c\/p\u003e\n\n\u003cp\u003eFinally, six patients were excluded based on interpretations of criteria that were not explicitly defined in the protocol itself — such as KRAS mutation status (a specific cancer gene change), liver metastases (cancer spread to the liver), or tumor marker levels.\u003c\/p\u003e\n\n\u003cp\u003eNotably, most of these patients went on to receive standard-of-care therapies afterward. Their subsequent treatments included chemotherapy alone, targeted therapy alone, combinations of chemotherapy with targeted therapy, chemotherapy with immune checkpoint inhibitors, and targeted therapy with immune checkpoint inhibitors.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe central message is direct: \u003cstrong\u003erigid eligibility criteria exclude stable patients who might benefit from investigational treatments.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eBecause roughly 1 in 7 screen failures were potentially modifiable, a substantial number of additional patients could have joined these trials if the criteria had been thoughtfully adjusted. Organ function and blood count rules accounted for 43% and 25% of those modifiable exclusions, respectively.\u003c\/p\u003e\n\n\u003cp\u003eWhy do these rules exist? Largely for historical reasons. They were built for traditional cytotoxic chemotherapy, which is far harder on the body than many modern targeted drugs. Those old standards may simply not fit the safety profiles of today's treatments.\u003c\/p\u003e\n\n\u003cp\u003eEvidence from other cancers supports this view. Patients excluded under strict eligibility rules have gone on to tolerate standard-of-care treatments well, even when their blood counts and organ function values sat near threshold limits. Trial access has already been broadened successfully in other areas — including for patients with brain metastases, human immunodeficiency virus (HIV) infection, and prior or concurrent cancers. That success sets a precedent.\u003c\/p\u003e\n\n\u003cp\u003eThe stakes are high for pancreatic and biliary cancers specifically. These patients often have borderline liver dysfunction, and their median overall survival is only about 12 months. For them, trial participation and completion are crucial to advancing treatment options and improving outcomes.\u003c\/p\u003e\n\n\u003cp\u003eAny changes to eligibility criteria must still carefully balance wider access against patient safety and scientific validity. The goal is not to remove safeguards — it is to make sure safeguards actually match the risks.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe authors are candid about the study's weaknesses.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetrospective design.\u003c\/strong\u003e Looking backward at records limits how firmly cause and effect can be established.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle institution.\u003c\/strong\u003e All patients came from one cancer center, so findings may not fully apply elsewhere.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubjective judgment.\u003c\/strong\u003e Even with two independent oncologists and agreement from co-investigators, deciding whether an exclusion was \"potentially modifiable\" involves interpretation and is prone to bias.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIncomplete records.\u003c\/strong\u003e The review may have missed some possible modifications to eligibility criteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited follow-up.\u003c\/strong\u003e Data after screening failure were incomplete, including how well patients tolerated subsequent standard treatments and what side effects they experienced.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTo address these gaps, the authors call for future research that \u003cstrong\u003eprospectively\u003c\/strong\u003e evaluates the impact of broadened eligibility criteria — that is, studying patients forward in time rather than looking back — with attention to both trial outcomes and patient safety in pancreaticobiliary cancers.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Next Steps\u003c\/h2\u003e\n\n\u003cp\u003eBased on their findings, the researchers offer several concrete recommendations.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRe-examine rigid organ function criteria\u003c\/strong\u003e, especially for pancreaticobiliary cancers, where borderline liver dysfunction is common.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider a flexible, data-driven strategy.\u003c\/strong\u003e Instead of fixed cutoffs, criteria could be adjusted based on real-time feedback from ongoing study data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModernize trial design.\u003c\/strong\u003e Decentralized protocols, hybrid visit models (combining in-person and remote check-ins), and risk-adaptive approaches could address the logistical and safety concerns that deter participation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImprove patient education.\u003c\/strong\u003e Better communication about what trials involve could correct misconceptions, and researchers should capture detailed reasons whenever a patient declines.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStrengthen biomarker testing strategies.\u003c\/strong\u003e Early molecular profiling could streamline patient selection and cut down on unnecessary screening procedures.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFix operational bottlenecks.\u003c\/strong\u003e Screening errors (9%) and research team logistics (8%) point to coordination gaps between clinical research teams and treating physicians.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThese recommendations align with a broader movement in oncology. The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research launched initiatives beginning in 2017 to modernize trial eligibility, addressing barriers such as brain metastases, organ function requirements, concurrent malignancies, HIV status, and age restrictions. In 2021, those guidelines expanded to cover washout periods, concomitant medications (other medicines taken at the same time), prior therapies, laboratory parameters, and performance status.\u003c\/p\u003e\n\n\u003cp\u003eOne caution is repeated throughout: any relaxation of criteria must preserve both patient safety and scientific integrity. Broader access should never come at the cost of trustworthy results.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat are potentially modifiable exclusions in cancer trials?\u003c\/h3\u003e\n\u003cp\u003ePotentially modifiable exclusions are reasons a patient failed screening that might have been safely changed or waived. In a review of 509 patients with pancreatic or biliary tract cancer, 69 (13.6%) had such exclusions. Most involved borderline laboratory values, like mildly abnormal liver or kidney tests or blood counts just below cutoff limits, rather than true safety threats.\u003c\/p\u003e\n\u003ch3\u003eHow common are potentially modifiable exclusions in pancreatic and biliary cancer trials?\u003c\/h3\u003e\n\u003cp\u003eIn a review of 509 patients with pancreatic or biliary tract cancer who consented but could not join trials, about 1 in 7 (13.6%, or 69 patients) had exclusions that might have been safely relaxed. These were spread evenly across 18 trials, so no single study was responsible. Most involved borderline organ function or blood count values.\u003c\/p\u003e\n\u003ch3\u003eWhat were the most common reasons patients failed screening?\u003c\/h3\u003e\n\u003cp\u003eAmong 509 patients, the three most common reasons for screening failure were: patient declined or withdrew consent (99 patients, 19%), coexisting severe comorbidities (59 patients, 12%), and suboptimal organ function (56 patients, 11%). Other reasons included absence of a required biomarker, screening error, research team logistics, and lack of a biospecimen.\u003c\/p\u003e\n\u003ch3\u003eWhat happened to patients who were excluded from trials due to modifiable reasons?\u003c\/h3\u003e\n\u003cp\u003eMost patients with potentially modifiable exclusions went on to receive standard-of-care therapies afterward. Their subsequent treatments included chemotherapy alone, targeted therapy alone, combinations of chemotherapy with targeted therapy, chemotherapy with immune checkpoint inhibitors, and targeted therapy with immune checkpoint inhibitors. The review did not fully capture how well they tolerated these later treatments.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of relaxing eligibility criteria for cancer trials?\u003c\/h3\u003e\n\u003cp\u003eAny changes to eligibility criteria must still carefully balance wider access against patient safety and scientific validity. The goal is not to remove safeguards but to make sure safeguards actually match the risks. The authors emphasize that broader access should never come at the cost of trustworthy results, and they call for prospective research to evaluate broadened criteria.\u003c\/p\u003e\n\u003ch3\u003eIf I have pancreatic or biliary tract cancer and was told I failed clinical trial screening because of borderline liver, kidney, or blood test results, should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eRoughly 1 in 7 screen failures in pancreatic and biliary tract cancer involved exclusions that expert reviewers judged potentially modifiable, mostly borderline liver or kidney values and blood counts just below cutoff limits rather than true safety threats. Two experienced oncologists classified an exclusion as potentially modifiable when values sat within 10%–15% of the threshold and were unlikely to affect safety or study integrity. A second opinion can help determine whether rigid criteria, many inherited from the chemotherapy era, actually apply to your situation. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Broadening the gates - Analysis of potentially modifiable study entry criteria in cancer trials\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Fen Saj, MD, DM; Felicity K. Namayanja, MBChB, MPH; Lianchun Xiao, MS; Mitesh J. Borad, MD; Robin Kate Kelley, MD; Lipika Goyal, MD, MPhil; Nilofer S. Azad, MD; Melinda Bachini; Stacie Lindsey, BA; Shubham Pant, MD; Juan W. Valle, MBChB, MSc, FRCP; Lola A. Fashoyin-Aje, MD, MPH; Milind Javle, MD\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInstitutions:\u003c\/strong\u003e The University of Texas MD Anderson Cancer Center (Houston, Texas); Mayo Clinic (Scottsdale, Arizona); Helen Diller Family Comprehensive Cancer Center, University of California–San Francisco; Stanford Cancer Center (Palo Alto, California); Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine (Baltimore, Maryland); The Cholangiocarcinoma Foundation (Herriman, Utah); University of Manchester (Manchester, UK); and the Oncology Center of Excellence, US Food and Drug Administration (Silver Spring, Maryland)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cancer (published by Wiley Periodicals LLC on behalf of the American Cancer Society)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Received 24 March 2025; Revised 18 August 2025; Accepted 4 November 2025; published 2026; DOI: 10.1002\/cncr.70227\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47738971488412,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/opening-the-gates-how-flexible-eligibility-rules-could-let-more-pancreatic-and-biliary-cancer-patients-join-clinical-trials","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}